Trial · NCT07887282
The Effects of Interval Respiratory Muscle Training on Athletic Performance
NCT07887282, Not applicable, Completed, Ondokuz Mayıs University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Interval Respiratory Muscle Training on Athletic Performance. Trials, record NCT07887282. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887282
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Interval Respiratory Muscle Training on Athletic Performance
- NCT number
- NCT07887282
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 23 participants, actual
- Lead sponsor
- Ondokuz Mayıs University
- Conditions
- Respiratory Muscle Training, Inspiratory Muscle Strength, Maximal Oxygen Consumption
- Interventions
- IMT %40 MIP, IMT %50-60-70-80
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in maximal inspiratory pressure (MIP) | Baseline and Week 4 (end of the intervention). | Maximal inspiratory pressure (MIP) will be measured using a device with a respiratory pressure measurement function and expressed in cmH2O. Change will be calculated as the Week 4 value minus the baseline value. |
| Primary | Change in Maximal Expiratory Pressure (MEP) | Baseline and Week 4 (end of the intervention). | Maximal expiratory pressure was measured from total lung capacity against an occluded airway using a digital respiratory pressure meter (MicroRPM) and expressed in cmH2O. Change was calculated as Week 4 minus baseline. |
| Secondary | Change in forced vital capacity (FVC) | Baseline and Week 4 (end of the intervention). | Forced vital capacity (FVC) will be measured by spirometry and expressed in liters. Change will be calculated as the Week 4 value minus the baseline value. |
| Secondary | Change in Forced Expiratory Volume in 1 Second (FEV1) | Baseline and Week 4 (end of the intervention). | Volume exhaled in the first second of a forced exhalation maneuver was measured using spirometry, expressed in liters (L). |
| Secondary | Change in FEV1/FVC Ratio | Baseline and Week 4 (end of the intervention). | The ratio of forced expiratory volume in 1 second to forced vital capacity was assessed using spirometry, expressed as a percentage (%). |
| Secondary | Change in Slow Vital Capacity (SVC) | Baseline and Week 4 (end of the intervention). | Vital capacity measured during relaxed, unforced breathing using spirometry, expressed in liters (L). |
| Secondary | Change in Maximal Voluntary Ventilation (MVV) | Baseline and Week 4 (end of the intervention). | Maximal volume of air ventilated over a 12-second sprint breathing protocol was extrapolated to liters per minute (L/min). |
| Secondary | Change in Seated Medicine Ball Throw Distance | Baseline and Week 4 (end of the intervention). | Upper body explosive power was measured by throwing a 3 kg medicine ball overhead from a seated position with the back supported against a wall. The maximum distance achieved across three trials was recorded in centimeters (cm). |
| Secondary | Change in 30-Second Modified Push-Up Repetitions | Baseline and Week 4 (end of the intervention). | Upper body muscular endurance was evaluated by counting the maximum number of correctly executed push-up repetitions performed within 30 seconds. |
| Secondary | Change in 1-Minute Sit-Up Repetitions | Baseline and Week 4 (end of the intervention). | Abdominal muscular endurance was evaluated by recording the maximum number of correctly executed sit-up repetitions completed in 60 seconds. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887282
GET https://conductscience.org/api/trials/v1/NCT07887282/registered